ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

OMNIPAQUE 300
Imaging agents
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

OMNIPAQUE 300 Rx

Generic Name and Formulations:
Iohexol 647mg (equivalent to 300mg of organic iodine) per mL; soln; preservative-free.

Company:
GE Healthcare

Therapeutic Use:

Indications for OMNIPAQUE 300:

For intrathecal administration in adults including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography, ventriculography). IV: In adults, for aortography including studies of the aortic arch, abdominal aorta and its branches, contrast enhancement for computed tomographic head and body imaging, cerebral arteriography, peripheral venography (phlebography), and excretory urography. In children, for angiocardiography (ventriculography), excretory urography, and contrast enhancement for computed tomographic head imaging. Oral/body cavity use: In adults, for arthrography and hysterosalpingography. In children, for examination of the gastrointestinal tract.

Adults and Children:

See literature for dosing based on procedure.

Contraindications:

Local or systemic infection (w. myelography). Concomitant corticosteroids with intrathecal administration. Immediate repeat myelography in the event of technical failure. Hysterosalpingography: during menstrual period or when menstural flow is imminent; genital tract infection, pregnant women.

Warnings/Precautions:

Do not administer Omnipaque 350 intrathecally: severe reactions may occur (eg, death, convulsion, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, brain edema). To be used by trained personnel in appropriate facilities. History of epilepsy. Severe cardiovascular disease. Chronic alcoholism. Multiple sclerosis. Diabetes. Multiple myeloma. Carcinoma. Resistant anuria. Pheochromocytoma. Homozygous sickle cell disease. Homocystinuria: avoid. Chronic pulmonary emphysema. Thyroid disorder. Patients with evidence of inadvertant intracranial entry of large or concentrated bolus of contrast medium: increased risk of seizures; consider prophylactic barbiturate therapy. Direct intracisternal or ventricular administration for standard radiography: not recommended. Maintain elevation of head during procedure, on the stretcher, or in bed. Avoid excessive and active patient movement or straining. Hepatic or renal impairment. Renal transplant recipients. Elderly. Pregnancy (Cat.B). Nursing mothers: bottle feeding may be substituted for breast feeding for 24hrs following administration.

Interactions:

Concomitant drugs that lower seizure threshold (eg, phenothiazines, MAOIs, tricyclics, CNS stimulants, analeptics, major tranquilizers, antipsychotics): not recommended; discontinue 48hrs and for at least 24hrs post-procedure. May reduce iodine-binding capacity of thyroid tissue for up to 2 weeks.

See Also:

OMNIPAQUE 240

OMNIPAQUE 350

Pharmacological Class:

Radiographic contrast medium.

Adverse Reactions:

Intrathecal: headache, backache, neckache, stiffness, GI upset; allergic reactions (may be severe). IV: inj site reactions, arrhythmias, angina/chest pain, hypotension, vertigo, vision abnormalities, headache, taste perversion, GI upset. Body cavities: pain, swelling, heat. Oral: diarrhea, nausea, vomiting, abdominal pain, flatulence, headache; children: also, fever, hypotension, urticaria. Arthrography: joint pain/swelling, heat sensation. ERP/ERCP: transient pain, hypertension, somnolence, burning, GI upset. Hysterosalpingography: transient pain, somnolence, fever, nausea. Herniography: pain, headache, unwell feeling, diarrhea, flatulence.

How Supplied:

Omnipaque 240 (200mL)—10; Omnipaque 300 (200mL, 500mL)—10; Omnipaque 350 (500mL)—10

Sign Up for Free e-newsletters